Entera Bio (ENTX) Gross Margin (2021 - 2024)

Entera Bio has disclosed Gross Margin across 3 years of filings, most recently posting 15.79% for Q2 2024.

• Quarterly Gross Margin changed N/A year-over-year to 15.79% in Q2 2024, while the trailing twelve-month figure through Mar 2025 was 4.04% (changed N/A YoY) and the FY2024 annual result came in at 4.97%, changed N/A from the prior year.
• Gross Margin slipped to 15.79% in Q2 2024, from 42.86% in the prior quarter.
• Over five years, Gross Margin peaked at 53.57% in Q3 2021 and troughed at 9.17% in Q2 2021.
• A 3-year average of 29.23% and a median of 25.0% in 2022 frame the typical range for Gross Margin.
• Biggest YoY gain for Gross Margin was 2528 bps in 2022; the steepest drop was 3291 bps in 2022.
• Tracing ENTX's Gross Margin over 3 years: stood at 17.58% in 2021, then jumped by 144 bps to 42.86% in 2022, then tumbled by 63 bps to 15.79% in 2024.
• Business Quant data shows ENTX's Gross Margin at 15.79% in Q2 2024, 42.86% in Q4 2022, and 25.0% in Q3 2022.